Kiromic Biopharma rises on plans to begin trial for cancer cell therapy
11/05/2022 14:17
** Shares of gene-editing co KRBP.O rise as much as 39.02%
at $0.57 before the bell
** Kiromic Biopharma says it will submit revised application
to FDA to begin trial for its cancer cell therapy Procel in H2
of the year urn:newsml:reuters.com:*:nBwbjZCJta
** In July 2021, FDA placed co's IND submission on clinical
hold after chemistry, manufacturing and control
concerns urn:newsml:reuters.com:*:nBw6hvKhba
** KRBP says it will not proceed with previously
contemplated Type A meeting with FDA, and will directly submit
amended IND
** KRBP CEO Pietro Bersani says co aims to begin clinical
trial for Procel by end of Q4 2022
(Reporting by Nandhini Srinivasan)
((Nandhini.Srinivasan@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site